Biotech & Life Sciences
Biotech marketing for investor relations, scientific communications, and commercial readiness
Empire325 is a biotech marketing agency for pre-clinical, clinical, and commercial-stage biotech, pharma, medtech, and diagnostics companies. We build investor relations programs, scientific communications, KOL engagement, and growth marketing — respecting FDA promotional rules, SEC fair disclosure requirements, and clinical-trial blackout periods.
Book a 15-min biotech strategy callTL;DR: Empire325 biotech marketing combines investor relations, scientific communications, KOL engagement, and commercial-readiness marketing. Every engagement respects FDA, SEC, MLR, and quiet-period constraints — built alongside your regulatory counsel, not around them.
What Empire325 delivers in biotech
01
Investor relations
IR site builds, quarterly earnings communications, IPO/SPAC roadshow support, fact sheets, pipeline trackers, and investor-day materials. Reg-FD aligned.
02
Scientific communications
Pipeline narrative, MOA explainers, publication strategy support, conference presentations, and KOL-facing content. Scientific accuracy under MLR review.
03
KOL programs
Key Opinion Leader identification, advisory board support, scientific symposia, peer-to-peer education programs. Aligned with corporate compliance and Sunshine Act reporting.
04
Commercial readiness
Pre-launch market shaping, payer-facing content, HCP digital presence, patient-advocacy partnerships. Designed for the 12-24 months before approval.
05
Partnership / BD marketing
Pharma-partnership marketing for licensing, collaboration, and M&A. Positioning content for BD conversations at JPM Healthcare, BIO, AACR, ASH, ASCO.
06
Compliance-aware analytics
Marketing attribution that respects HIPAA where applicable, plus PII/PHI handling appropriate to the buyer audience (HCP, patient, investor, partner).
Biotech marketing FAQ
What does a biotech marketing agency do?
A biotech marketing agency builds investor relations programs, scientific communications, KOL (Key Opinion Leader) engagement, and commercial-readiness marketing for biotech, pharma, and life sciences companies. Empire325 biotech engagements span pre-clinical positioning, clinical milestone communications, IPO/SPAC roadshow support, partnership marketing, and (post-approval) commercial launch programs.
What's different about biotech marketing vs. typical B2B?
Three differences: (1) Audiences are highly technical (PIs, KOLs, regulators, institutional investors) requiring scientific accuracy, not consumer-style positioning. (2) Communications must respect SEC fair disclosure rules, FDA promotional restrictions, and clinical trial blackout periods. (3) Long timelines — pre-clinical to commercial can take 7-15 years, requiring sustained narrative investment without short-term traffic metrics as proof.
How does Empire325 handle FDA/SEC compliance in biotech marketing?
Every campaign and content piece enters a documented review pipeline aligned with the company's regulatory and legal counsel. We work alongside MLR (Medical/Legal/Regulatory) review teams, not around them. For investor-facing communications, we respect Reg FD, IPO quiet periods, and SEC Marketing Rule applicable provisions.
What biotech segments does Empire325 serve?
Pre-clinical and clinical-stage biotech, biopharmaceutical companies, medical device firms, diagnostics companies, contract research organizations (CROs), AI-drug-discovery platforms, gene therapy and cell therapy companies, and biotech-focused investors (VC funds, biotech hedge funds).
How much does biotech marketing cost?
Empire325 biotech engagements typically range $20K-$100K monthly retainers depending on scope, regulatory complexity, and IR/commercial mix. Implementation projects (IR site rebuilds, KOL programs, IPO marketing infrastructure) range $40K-$250K project-based. Discovery scoping is provided after a 30-minute call.